Efficacy Supplement Numbers On The Rise As Industry Braces For Patent Cliff
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Drug makers are squeezing more new and expanded indications out of approved drugs to compensate for patent expiries and the lagging pace of new drug approvals, according to an analysis from the Tufts Center for the Study of Drug Development.
You may also be interested in...
E.U. Recommends Novartis' CV Combo Rasilamlo
European regulators recommend approval of yet another combination antihypertensive from Novartis as the Swiss company attempts to soften the loss of patent protection on its blockbuster Diovan.
Tekturna Will Track Diovan’s Steady Growth To Blockbuster Status - Novartis
Novartis is hoping sales of its new blood pressure drug Tekturna will climb steadily as morbidity and mortality data amass, eventually leading it to blockbuster status on the same trajectory as top-selling Diovan
The Heart Of A Pipeline: Can Novartis Keep The Cardio Portfolio Beating?
The challenge of a generation shift in cardiovascular drugs is not new for Novartis, but the upcoming phase-out of Diovan through 2012 looks more difficult. As the firm prepares to lose Diovan exclusivity, its pipeline reflects an attempt to reprise the time-honored big pharma strategy that carried it through the loss of Lotrel in 2007: mix major efforts to develop novel, first-in-class agents with a push to accelerate its already marketed brands